News | August 03, 2022
Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee
he US FDA has issued six observations pursuant to the completion of the audit.
he US FDA has issued six observations pursuant to the completion of the audit.
Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Subscribe To Our Newsletter & Stay Updated
